10/31/14 GILD 112.00 Gilead Sciences $GILD Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
10/31/14 GILD 112.00 Gilead Sciences $GILD Hit a 52 week high of 116.83 Closing the day 10/31/14 at 112.00 -2.22 -1.94% With a day low of 110.76 and a total volume of 22,058,299.

GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/

GILD Gilead Sciences Recent Headline News

5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 107.78 (+0.74), VRTX: 112.64 (+1.79), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)

IBD 50 Caps Impressive 2-Week Rally
at Investor's Business Daily - Fri Oct 31, 5:47PM CDT
The IBD 50 just capped its best two-week performance in more than three years -- a run that's produced a batch of breakouts. The index rallied 9.4% over the past two weeks. That's the best two-week period since July 2011, when the IBD 50 roared...
ODFL: 72.87 (+0.51), AAP: 146.96 (+1.25), AKRX: 44.55 (+0.91), ILMN: 192.58 (-0.84), NXPI: 68.66 (+3.25), CDW: 30.84 (+0.71), CELG: 107.09 (+0.15), BIDU: 238.77 (+1.76), GILD: 112.00 (-2.22), JAZZ: 168.84 (-0.98), FLT: 150.56 (+8.01), FL: 56.01 (+0.16), AAPL: 108.00 (+1.02), AVGO: 86.25 (+3.86)

Final Glance: Biotechnology companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)

Fundamentals, Technicals Still Intact At Gilead Sciences
at Investor's Business Daily - Fri Oct 31, 4:36PM CDT
Some analysts called Gilead Sciences' third-quarter earnings report on Oct. 28 "sloppy." But make no mistake: It's still a company in growth mode. And its weekly chart doesn't look bad either. Gilead's (GILD) earnings per share slightly missed...
GILD: 112.00 (-2.22)

Midday Glance: Biotechnology companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)

AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), SHPG: 199.80 (+0.38), AMGN: 162.18 (+0.60), ABBV: 63.46 (+2.28)

Early Glance: Biotechnology companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)

Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 107.78 (+0.74), NEE: 100.22 (+0.31), V: 241.43 (+4.78), GILD: 112.00 (-2.22), DUK: 82.15 (-0.14), EXC: 36.59 (-0.11), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28), DTE: 82.16 (+0.17), SO: 46.36 (-0.09), MA: 83.75 (+0.62)

Gilead Sciences (GILD) Crosses Pivot Point Resistance at $115.51
Comtex SmarTrend(R) - Fri Oct 31, 8:58AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $113.06 today and have reached the first resistance level of $115.51. Should the shares continue to rise, the resistance pivots of $116.81 and $120.56 will be of interest.
GILD: 112.00 (-2.22)

Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 10.72 (+0.46), TTWO: 26.45 (+1.18), BIIB: 321.08 (+0.08), GILD: 112.00 (-2.22), CRL: 63.16 (+0.35), REGN: 393.72 (+0.92), CELG: 107.09 (+0.15)

Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 153.77 (+1.67), BIIB: 321.08 (+0.08), HON: 96.12 (+0.53), FB: 74.99 (+0.88), BMY: 58.19 (-0.79), MGM: 23.25 (+0.27), ATK: 116.96 (+6.77), YRCW: 21.44 (+3.24), UPS: 104.91 (+1.62), SLB: 98.66 (+1.04), CELG: 107.09 (+0.15), WPRT: 6.17 (+0.12), SBUX: 75.56 (-1.76), TTWO: 26.45 (+1.18), DO: 37.71 (-0.94), ETP: 64.43 (+0.41), GILD: 112.00 (-2.22), ARR: 3.96 (-0.01), CMG: 638.00 (-1.68), MPEL: 27.14 (+0.78), WNC: 10.30 (+0.81), CRL: 63.16 (+0.35), AAPL: 108.00 (+1.02), REGN: 393.72 (+0.92)

5 Things McKesson Corporation's Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Oct 30, 5:23PM CDT
Now that the dust has settled after McKesson Corporation 's second-quarter financial results were announced on Tuesday, it's time to look past the numbers. Yes, McKesson beat expectations for earnings and revenue -- but the real story is what's...
MCK: 203.41 (-0.07), GILD: 112.00 (-2.22), RAD: 5.25 (+0.07)

Netflix and Gilead Will See More Gains, Says Thornburg Value Manager
at The Street - Thu Oct 30, 4:54PM CDT
Gilead shares have had a tremendous run this year, but the valuation remains cheap considering its sales potential in the area of Hepatitis C.
NFLX: 392.77 (+13.76), PAHC: 25.92 (+0.27), GILD: 112.00 (-2.22)

Veeva Systems Flies High On Cloud For Life Sciences
at Investor's Business Daily - Thu Oct 30, 4:31PM CDT
Before founding software company Veeva Systems in 2007, Peter Gassner was certain of two things. He wanted the technology to be cloud-based and to address critical issues for a specific industry. He decided to focus on life sciences. "We could have...
VEEV: 29.78 (+0.99), IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), ORCL: 39.05 (+0.55), CRM: 63.99 (+2.27), NVS: 92.69 (+0.74)

Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 3.13%
Comtex SmarTrend(R) - Thu Oct 30, 3:35PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $110.60 to a high of $114.35. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $114.13 on volume of 13.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 112.00 (-2.22)

SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 3.13% Gain
Comtex SmarTrend(R) - Thu Oct 30, 3:34PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $110.60 to a high of $114.35. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $114.13 on volume of 13.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 112.00 (-2.22)

Most active Nasdaq-traded stocks
AP - Thu Oct 30, 12:17PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 33.09 (+1.27), GILD: 112.00 (-2.22), FB: 74.99 (+0.88), CDTI: 3.12 (-0.79), ARCP: 8.87 (-0.55), MSFT: 46.95 (+0.90), INTC: 34.01 (+1.43), GRPN: 7.31 (+1.32), AAPL: 108.00 (+1.02), CSCO: 24.47 (+0.39), RFMD: 13.01 (+0.94)

Gilead Sciences Inc. (GILD) Stock Research Links

GILD Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Miraculous Medical Team Effort Saves Newborn's Life

Updated Category News Views 3

A Medical Feat: Teamwork at Its Pinnacle You want a story that restores your faith in humanity? Well, this one from Memorial Healthcare System and Joe DiMaggio Children's Hospital might just do the trick. The tale of baby Jay'ce, born with a neck mass threatening his breath, is straight out of a medical drama—albeit without the Hollywood scriptwriters' spin. It’s rare...

Continue Reading
Unicycive Faces Legal Heat Amid Stock Tumble

Updated Category News Views 2

Unicycive Therapeutics' Rough Ride In this wild market, sometimes even the most seasoned investors get blindsided. Unicycive Therapeutics (NASDAQ: UNC) shareholders are currently caught in a storm with their stock nose-diving by 39.1% on June 30, 2026. It's like being taken to the cleaners without the decency of a warning. Failed Expectations & FDA Blues Here's the...

Continue Reading
Saab Q3 2026: Major Contracts Fuel Impressive Growth

Updated Category News Views 6

Saab's Stellar Q3 Performance If there’s one picture capturing the essence of Saab’s third quarter in 2026, it's one brimming with contracts, cash, and sheer growth. They’re racking up tangible wins left and right, and if you're an investor who loves numbers doing a solid 30.6% high jump, Saab's buzzing red-hot. Key Contracts Putting Saab in the Spotlight The very...

Continue Reading
Divorce Expertise: Obenhaus Adds CDFA Credential

Updated Category News Views 3

Divorce isn't just a legal tangled mess; it's a financial minefield as well. Lindsey Obenhaus from Goranson Bain Ausley has beefed up her credentials with a Certified Divorce Financial Analyst® (CDFA®) designation, lending a sharper edge to her approach in divorce financials. When relationships turn sour, so do wallets, and Obenhaus aims to soften that blow for her...

Continue Reading
Cboe Clear's US Move: A New Chapter with SEC Nod

Updated Category News Views 4

Clearing the Path for New Beginnings The ink's barely dry on Cboe Clear U.S.'s recent SEC registration, and it's already setting tongues wagging among market old-timers. This move to clear binary securities options alongside futures isn't just a step up; it's a signal flare for ambitious innovation. The Nuts and Bolts: SEC Registration So, what's the big to-do? Cboe Clear...

Continue Reading
HYXI Eyes European Growth with Product Matrix Launch

Updated Category News Views 4

Unveiling the Future: HYXI's Grand Showcase You know you're onto something big when nearly 60 industry insiders travel halfway across the globe to see what you've got cooking. That's exactly what went down at HYXI's Hangzhou headquarters on October 21, 2026. Under a snazzy theme, "See Where It Begins, Shape the Future," this European Partner Day was more than just a...

Continue Reading
LianLian and PayPal: Transforming Creator Payouts Globally

Updated Category News Views 8

Social Commerce Meets Seamless Payments Ah, the sweet smell of global payments getting a makeover—it’s about time! LianLian Global's new dance with PayPal (NASDAQ:PYPL) is turning heads, pushing boundaries, and setting an entirely new stage for the gig economy. With LianLian’s clients now able to zap payments directly into PayPal and Venmo accounts, creators and...

Continue Reading
Coastal’s Class Action: Credit Missteps Lead to 43% Drop

Updated Category News Views 3

Coastal's Big Misstep: A Costly Setback Hey, when a stock drops like a rock on negative news, it's a sign for those on the sidelines to take note. Coastal Financial Corporation, known by its ticker NASDAQ: CCB, felt the hard slap of market reality when a single-day nosedive shaved off a hefty 43% of its stock value. It's all thanks to a whopper of a securities class...

Continue Reading
Amber Intl Unveils AGM Outcomes, Strategic Moves

Updated Category News Views 5

Diving Into Amber International's AGM Decisions Ah, the hum of shareholder meetings—a fancy little dance of approvals and resolutions! That's exactly what went down on October 23, 2026, for Amber International Holding Limited. A fresh roster, some hefty share awards, and strategic decisions wrapped up their recent annual gathering. Shed the lawyer-speak and let's get...

Continue Reading
Estrogen Patch Struggles: Menopause Care Needs a Boost

Updated Category News Views 3

Troublesome Estrogen Patch Shortages Hit Hard You'd think getting a prescription filled would be a simple task, right? Well, think again. Midi Health shines a glaring light on how the supposed ease of getting hormone therapy is anything but for many women in 2026. Out of those scrambling for estradiol patches, 44% hit roadblocks in pharmacies, and a third hit an all-out...

Continue Reading

Top 5 Most Recently Viewed Articles

Verizon Teams Up with Google to Enhance Customer Experience

Updated Category News Views 141

Verizon's Innovative Partnership with Google One AI Premium Verizon is making waves in the telecommunications industry by rolling out an exciting new offering for its myPlan and myHome customers. The integration of Google One AI Premium provides users an impressive array of features designed to enhance productivity and convenience at an unbeatable value. What is Google...

Continue Reading
Unlock Unbeatable Savings: FSA Store's Black Friday Offerings

Updated Category News Views 261

Maximize Your Savings This Black Friday with FSA Store The holiday season is just around the corner, and it's the perfect time for consumers to unlock amazing deals. FSA Store has stepped up to offer excellent discounts during Black Friday. With attractive promotions, shoppers can stretch their tax-free Flexible Spending Account (FSA) funds before they expire. The clock...

Continue Reading
Snowflake Expands Its AI Capabilities with Select Star Deal

Updated Category News Views 707

Snowflake's Strategic Acquisition of Select Star Snowflake Inc. (NYSE: SNOW) is making a significant stride in the enterprise data landscape by acquiring Select Star. This acquisition addresses a critical challenge faced by businesses: the need to streamline and contextualize data scattered across various platforms. In today’s data-driven world, having clear insights...

Continue Reading
Effective Roth Conversion Strategies for Seniors with 401(k) Assets

Updated Category News Views 96

Retirees faced a harsh reality back in 2024 when it came to Required Minimum Distributions (RMDs) from their retirement accounts. For many, this was less about financial planning and more about surviving an unexpected tax onslaught. Imagine sitting on a $1 million 401(k), feeling pretty good about that nest egg until the IRS comes knocking, demanding withdrawals that...

Continue Reading
Nippon Steel's High-Stakes Dance to Secure U.S. Steel Deal

Updated Category News Views 132

Nippon Steel’s Drive to Acquire U.S. Steel Reaches a Critical Stage Nippon Steel Corp.’s vice chairman, Takahiro Mori, is heading to the United States to press forward on the company’s proposed $15 billion purchase of United States Steel Corp. His trip centers on meetings with key U.S. officials to work through concerns about foreign ownership and what it might mean...

Continue Reading